Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05620836 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa (HS)
A Phase 3 study, sponsored by Incyte Corporation.
- Completed
- Registry status
- Phase 3
- Development phase
- 619
- Enrollment target
NCT05620836 is a Phase 3 study that has completed, run by Incyte Corporation. The registered enrollment target is 619 participants.
The verdict
NCT05620836, a Phase 3 study, has completed, sponsored by Incyte Corporation.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 619 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy and safety of Povorcitinib (INCB054707) in participants with moderate to severe Hidradenitis Suppurativa (HS) over a 12-week placebo-controlled period, followed by a 42-week extension period.
Interventions
- DRUG Placebo
- DRUG Povorcitinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 619 participants |
| Start Date | 2023-02-22 |
| Est. Completion | 2025-11-21 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05620836
The ClinicalTrials.gov registry entry for NCT05620836 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 619 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Incyte Corporation, which has 239 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05620836 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05620836 about?
NCT05620836 is a clinical study titled "A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa (HS)". The purpose of this study is to evaluate the efficacy and safety of Povorcitinib (INCB054707) in participants with moderate to severe Hidradenitis Suppurativa (HS) over a 12-week placebo-controlled period, followed by a 42-week extension period.
What is the current status of trial NCT05620836?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 619 participants. The study started on 2023-02-22. Estimated completion is 2025-11-21.
What interventions are being tested in trial NCT05620836?
The interventions under investigation include: Placebo (DRUG), Povorcitinib (DRUG).
Who is sponsoring clinical trial NCT05620836?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.